Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Zitel-ZITL What's Happening -- Ignore unavailable to you. Want to Upgrade?

To: CMason who wrote (12463)	10/31/1997 5:09:00 PM
From: Jim Roof	Respond to of 18263

Exactly how many staff members does it take to get FDA approval? Sure, Abbott could pay just to put Biotime out of the picture but don't you see the irony here? That is still an endorsement of the efficacy of the product. If not, then they should let some 'sucker' pick up the product instead. I have not seen the actual contract, but my guess would be that any such agreement would be predicated upon good faith efforts to market Hextend. As for whether it will be prescribed, the word I hear is that surgeons who used it have immediately recognized its superiority over other hetastarches and salines. As for third party payors I can only guess. But my guess is that Hextend will in the long haul represent a savings as the complications surrounding its use are less severe and less numerous than with other approaches. It is also still cheaper than whole blood and albumin (about 1/5 the cost of that). So, where a 600/litre solution might do just the job I do not think an insuror would put up much of a fight against a 125/litre alternative. Sure, it's a gamble. I just think that the deck is stacked in favor of going long on this one. I am in at 9 (sa). I think it hits 35 in 3-4 weeks. Good luck, Jim